Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 14/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.70 |
| ▸ | HPGD | P15428 | 13/20 | 0.70 |
| ▸ | LMNA | P02545 | 12/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.70 |
| ▸ | RAB9A | P51151 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | GAA | P10253 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 8/20 | 0.70 |
| ▸ | PRNP | P04156 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 12/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | PTPRR | Q15256 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30960490 | 1.00 | MEN1 (0.70) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL22994346 | 0.92 | ALDH1A1 (0.74) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL30960484 | 0.92 | ALDH1A1 (0.74) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL30960487 | 0.85 | MEN1 (0.60) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL22994351 | 0.85 | MEN1 (0.60) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL22994344 | 0.84 | MEN1 (0.52) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL30960485 | 0.84 | MEN1 (0.52) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL22994342 | 0.82 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL30960491 | 0.82 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL22978670 | 0.81 | MEN1 (0.74) | MEN1KMT2AALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113402479-B | Antitumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-113402479-A | Anti-tumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2021-09-17 | — | — | CN | claimed |
| CN-110437176-B | Anti-tumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2021-08-03 | — | — | CN | claimed |
| CN-113402479-B | Antitumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023104182-A1 | ANTI-TUMOR COMPOUND AND USE THEREOF | 先声药业有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-4015510-A1 | ANTI-TUMOUR COMPOUND BASED ON JWA GENE ACTIVATION AND HER2 DEGRADATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Simcere Pharmaceutical Co. Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| CN-113402479-A | Anti-tumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-110437176-B | Anti-tumor compound based on JWA gene activation and HER2 degradation, preparation method and application thereof | 先声药业有限公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021027045-A1 | ANTI-TUMOUR COMPOUND BASED ON JWA GENE ACTIVATION AND HER2 DEGRADATION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 周建伟 | 2021-02-18 | — | — | WO | disclosed |
| US-20210047313-A1 | ANTITUMOR COMPOUND FOR ACTIVATING JWA GENE AND DEGRADING HER2, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF | SIMCERE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047313-A1 | ANTITUMOR COMPOUND FOR ACTIVATING JWA GENE AND DEGRADING HER2, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | MEN1 2781/4885KMT2A 152/4885ALDH1A1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.